TY - JOUR AB - Tumor-associated antigens recognized by cellular or humoral effectors of the immune system are potential targets for antigen-specific cancer immunotherapy. NY-ESO-1 is one of the most immunogenic cancer/testis (CT) antigens and emerges as the potential candidate for specific immunotherapy. We studied mRNA expression status of NY-ESO-1 in 63 cases of NSCLCs using the real-time reverse transcription PCR to examine the relationship between its expression and clinicopathological features. NY-ESO-1 expression was present in 20 (32%) of 63 NSCLC cases and significantly increased with the advancement of disease stage in TNM classification (P=0.013), especially related to lymph node metastasis (P=0.020). Moreover, frequency of NY-ESO-1 expression was related to the degree of pathological differentiation (P=0.035). The quantity of NY-ESO-1 expression by real-time RT-PCR was not correlated with any clinicopathological factor. Our results demonstrate that the NY-ESO-1 expression was frequently present in primary NSCLC, especially advanced cases with lymph node metastasis. In addition, the high incidence of NY-ESO-1 expression in NSCLC suggests the possibility of a specific immunotherapy for NSCLC. AD - Department of Cancer and Thoracic Surgery, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan null AU - Konishi,Juichiro AU - Toyooka,Shinichi AU - Aoe,Motoi AU - Omura,Yasushi AU - Washio,Kazuhiro AU - Tsukuda,Kazunori AU - Shimizu,Nobuyoshi DA - 2004/05/01 DO - 10.3892/or.11.5.1063 EP - 1067 IS - 5 JO - Oncol Rep PY - 2004 SN - 1021-335X 1791-2431 SP - 1063 ST - The relationship between NY-ESO-1 mRNA expression and clinicopathological features in non-small cell lung cancer T2 - Oncology Reports TI - The relationship between NY-ESO-1 mRNA expression and clinicopathological features in non-small cell lung cancer UR - https://doi.org/10.3892/or.11.5.1063 VL - 11 ER -